Clinical Trials · NCT05822544
Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes
- Phase
- Phase 1
- Recruitment status
- Recruiting
- Sponsor
- OrsoBio, Inc
- Enrollment
- 564
- Start date
- Apr 2023
- Locations
- 4 sites, New Zealand
- Primary endpoint
- Incidence of TLC-6740 treatment-emergent adverse events